Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
3.595
-0.135 (-3.62%)
Jan 23, 2025, 11:47 AM EST - Market open
Genfit Employees
Genfit had 159 employees as of December 31, 2023. The number of employees increased by 11 or 7.43% compared to the previous year.
Employees
159
Change (1Y)
11
Growth (1Y)
7.43%
Revenue / Employee
$542,297
Profits / Employee
$150,079
Market Cap
177.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
GNFT News
- 9 days ago - GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 2 months ago - GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 - GlobeNewsWire
- 2 months ago - GENFIT Reports Third Quarter 2024 Financial Information - GlobeNewsWire
- 4 months ago - Top 4 Health Care Stocks That May Keep You Up At Night - Benzinga
- 4 months ago - GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval - GlobeNewsWire
- 6 months ago - GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewsWire
- 7 months ago - GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH - GlobeNewsWire
- 8 months ago - GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis - GlobeNewsWire